Avascular necrosis of bone following combination chemotherapy for acute lymphocytic leukemia

1985 ◽  
Vol 13 (5) ◽  
pp. 269-272 ◽  
Author(s):  
Carolyn Felix ◽  
Julie Blatt ◽  
Mark A. Goodman ◽  
Jocelyn Medina
Keyword(s):  
Avascular Necrosis ◽  
Combination Chemotherapy ◽  
Acute Lymphocytic Leukemia ◽  
Lymphocytic Leukemia ◽  
Avascular Necrosis Of Bone

Avascular necrosis of bone in neuroblastoma treated with combination chemotherapy

1984 ◽  
Vol 143 (2) ◽  
pp. 152-153 ◽  
Author(s):  
Eiichi Ishii ◽  
Nobuyuki Yoshida ◽  
Sumio Miyazaki
Keyword(s):  
Avascular Necrosis ◽  
Combination Chemotherapy ◽  
Avascular Necrosis Of Bone

scholarly journals Central Nervous System Therapy and Combination Chemotherapy of Childhood Lymphocytic Leukemia

Blood ◽  
1971 ◽  
Vol 37 (3) ◽  
pp. 272-281 ◽  
Author(s):  
RHOMES J. A. AUR ◽  
JOSEPH SIMONE ◽  
H. OMAR HUSTU ◽  
THOMAS WALTERS ◽  
LUIS BORELLA ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Complete Remission ◽  
Combination Chemotherapy ◽  
Acute Lymphocytic Leukemia ◽  
Viral Infections ◽  
Combined Therapy ◽  
Lymphocytic Leukemia ◽  
Intrathecal Methotrexate ◽  
Central Nervous System Relapse

Abstract In earlier combination chemotherapy regimens for childhood acute lymphocytic leukemia, nervous system leukemia terminated complete remission in over half the patients in a median time of 11 months. In the present study, cranial radiation (2400 R, 60Co) and intrathecal methotrexate given early in remission were added to combination chemotherapy in an attempt to prevent or delay central nervous system relapse and termination of complete remission. Of 35 consecutive children with previously untreated acute lymphocytic leukemia, 20 of 30 who attained remission and received all initial phases of therapy have been in continuous complete remission for 23 to 30 months. Complete remission was terminated by nervous system relapse in three patients and by hematological relapse in five. Two patients died in complete remission of viral infections and others experienced reversible drug toxicity. We conclude that this combined therapy reduces the incidence of nervous system relapse in the first 2 years and prolongs complete remission.

scholarly journals A Comparative Study of Two Regimens of Combination Chemotherapy in Acute Leukemia

Blood ◽  
1958 ◽  
Vol 13 (12) ◽  
pp. 1126-1148 ◽  
Author(s):  
EMIL FREI ◽  
JAMES F. HOLLAND ◽  
MARVIN A. SCHNEIDERMAN ◽  
DONALD PINKEL ◽  
GEORGE SELKIRK ◽  
...  
Keyword(s):  
Acute Leukemia ◽  
Survival Time ◽  
Median Survival ◽  
Combination Chemotherapy ◽  
Drug Toxicity ◽  
Acute Lymphocytic Leukemia ◽  
Lymphocytic Leukemia ◽  
Acute Myelocytic Leukemia ◽  
Myelocytic Leukemia ◽  
Remission Status

Abstract A comparative clinical trial of two regimens of combination chemotherapy has been accomplished in acute leukemia by four separate medical and pediatric services. Sixty-five patients were allocated at random to one of two treatment programs. Daily administration of methotrexate with daily 6-mercaptopurine has been compared to methotrexate every third day in the same total dose with daily 6-mercaptopurine. No difference in frequency of remission, extent of remission or toxicity was observed between the two groups. Among those patients who attained remission status, however, duration of remission (P = .05-.10) and of survival (P = <.05) was longer for the continuous group. All remissions in children occurred in acute lymphocytic leukemia, whereas all remission in adults were observed in acute myelocytic leukemia. The duration of remissions was somewhat shorter for children with acute lymphocytic leukemia than for adults with acute myelocytic leukemia. The frequency of remission, either partial or complete, was higher in children, however (36 per cent), than in adults (19 per cent), although the confidence limits for each figure overlap. The duration of acute leukemia in previously untreated patients did not influence response to therapy from the two antimetabolite regimens in this study. In patients who had had prior antimetabolite therapy, however, complete remissions were attained less often than in previously untreated patients. The toxic manifestations encountered during the administration of these antimetabolites are described. Seventeen deaths occurred during this study, of which 8 occurred in the first 10 days, presumably from leukemia and not drug toxicity. Five patients died with hypoplastic marrows ascribed to drug toxicity. The toxic manifestations were qualitatively and proportionately the same in patients who attained remission status, and in those patients who failed to remit, but who lived long enough to recognize the onset of remission if it were going to occur. No indication was obtained, therefore, that patients who attained remission were subjected to a greater toxic hazard, in order to achieve the therapeutic benefits observed, than those who did not remit. The median survival of patients who achieved remission was longer (p <.05) than for patients who did not remit. Since the survival time of remitters from relapse to death was almost identical with the survival time of nonremitters from onset of treatment to death, this difference can be accounted for by the time spent in remission and getting to remission. The median survival time from symptomatic onset for all children in this study was 12 months, and for adults, 7 months. The median in children is similar to that reported from other clinics. This is evidence that a comparative therapeutic trial in acute leukemia can be accomplished without recognizable compromise of patient welfare.

Etoposide and cytosine arabinoside combination chemotherapy for refractory acute lymphocytic leukemia in childhood.

1986 ◽  
Vol 4 (7) ◽  
pp. 1089-1093 ◽  
Author(s):  
N Esumi ◽  
S Todo ◽  
S Arakawa ◽  
S Imashuku
Keyword(s):  
Complete Remission ◽  
Allergic Reaction ◽  
Combination Chemotherapy ◽  
Cytosine Arabinoside ◽  
Drug Combination ◽  
Acute Lymphocytic Leukemia ◽  
Complete Response ◽  
Lymphocytic Leukemia ◽  
Childhood All ◽  
Heavily Pretreated

Eighteen children with refractory acute lymphocytic leukemia (ALL) who had been heavily pretreated, were treated with combination etoposide and cytosine arabinoside (ara-C) chemotherapy. Seventeen of these 18 patients were in their first to third relapses; the remaining patient had never responded to induction therapy. The drug combination of etoposide followed by ara-C was administered as an intravenous (IV) infusion twice a week for two consecutive weeks, a total of four doses. The dosage was 150 mg/m2/dose for each drug. Seven (39%) of the 18 patients attained a complete remission (CR) and three (17%) attained a partial remission (PR). Complete response was obtained in two of eight patients in first marrow relapse, and in five of nine patients in second and third relapse. Five patients achieved a CR after one course of therapy and two achieved a CR after two courses of therapy. Of three patients who had previously received teniposide, two attained a CR with this combination. The duration of these responses was brief with a median of 1 month, ranging from 0.5 to 3 months, with the exception of one case, which has been in remission for 2.5 + months. Although myelosuppression was observed, none of the patients died from infection or bleeding. Allergic reaction with fever and rash was observed in two patients. The efficacy of the etoposide and ara-C combination for refractory childhood ALL is encouraging in several current reinduction regimens.

scholarly journals Avascular necrosis of bone caused by combination chemotherapy without corticosteroids.

BMJ ◽  
1984 ◽  
Vol 288 (6413) ◽  
pp. 267-268 ◽  
Author(s):  
P G Harper ◽  
C Trask ◽  
R L Souhami
Keyword(s):  
Avascular Necrosis ◽  
Combination Chemotherapy ◽  
Avascular Necrosis Of Bone

Combination chemotherapy and radiotherapy for acute lymphocytic leukemia in adults: Results of CALGB protocol 7113

1979 ◽  
Vol 3 (6) ◽  
pp. 395-407 ◽  
Author(s):  
Edward S. Henderson ◽  
Carol Scharlau ◽  
M.Robert Cooper ◽  
Farid I. Haurani ◽  
Richard T. Silver ◽  
...  
Keyword(s):  
Combination Chemotherapy ◽  
Acute Lymphocytic Leukemia ◽  
Lymphocytic Leukemia

Combination chemotherapy for acute lymphocytic leukemia in adults: Results of a retrospective study in 82 patients

1980 ◽  
Vol 8 (2) ◽  
pp. 175-183 ◽  
Author(s):  
Sergio Amadori ◽  
Aldo Montuoro ◽  
Giovanna Meloni ◽  
Maria Antonietta Aloe Spiriti ◽  
Leonardo Pacilli ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Combination Chemotherapy ◽  
Acute Lymphocytic Leukemia ◽  
Lymphocytic Leukemia
Sign in / Sign up

Export Citation Format

Share Document